Discussions with leaders: Buvat and Weber test ChatGPT's familiarity with nuclear medicine knowledge and practice in an extended virtual conversation. . . . . ***Page 505***

Chemotherapy and cognitive impairment: Chiaravalloti and colleagues summarize brain imaging findings relevant to subsequent cognitive effects in patients undergoing chemotherapy for common oncologic diseases. . . . . ***Page 508***

PET imaging in vasculitis: Slart and colleagues provide an educational overview of the diagnostic role of ^{18}F-FDG PET/CT in patients with large-vessel vasculitis, medium-sized vessel vasculitis, and polymyalgia rheumatica. . . . . ***Page 515***

PRRT and NETs: Hindié and colleagues offer a brief review of the latest advances in peptide-receptor radionuclide therapy of neuroendocrine tumors of gastroenteropancreatic origin, including clinical trial results and promising combination therapies. . . . . ***Page 522***

AUC summary for lymphoscintigraphy: Donohoe and members of a collaborative work group summarize the key points of appropriate use criteria (AUC) developed for lymphoscintigraphy in sentinel lymph node mapping and in lymphedema, including clinical scenarios. . . . . ***Page 525***

Radioembolization in cholangiocarcinoma: Schaarschmidt and colleagues identify clinical and tumor-associated factors in improved median overall survival in patients with intrahepatic cholangiocarcinoma receiving radioembolization at 5 major tertiary-care centers. . . . . ***Page 529***

PET in large B-cell lymphoma: Michaud and colleagues assess the prognostic value of ^{18}F-FDG PET/CT parameters at baseline, interim, and end of treatment in patients with diffuse large B-cell lymphoma. . . . . ***Page 536***

[^{177}Lu]Lu-ofatumumab lymphoma therapy: Shim and colleagues report on in vitro studies, dosimetry, tumor targeting, and therapeutic efficacy with this radiolabeled human anti-CD20 antibody in a murine model of disseminated non-Hodgkin lymphoma. . . . . ***Page 542***

^{225}Ac-MACROPATATE for NETs: King and colleagues detail the design and production of a novel radioconjugate capable of chelating ^{225}Ac at room temperature and assess in vitro and in vivo studies of its potential for α-particle targeted peptide-receptor radionuclide therapy. . . ***Page 549***

^{89}Zr-DFO-bexmarilimab PET: Moisio and colleagues evaluate a humanized monoclonal antibody against common lymphatic endothelial and vascular endothelial receptor-1 in a rabbit model of renal fibrosis. . . . . ***Page 555***

Thyroid remnant ablation in GO: Oeverhaus and colleagues report on responses after ablation of thyroid remnants with radioactive iodine therapy in patients with unstable Graves' orbitopathy after subtotal thyroidectomy. . . . . ***Page 561***

PPQ/NETest validation for PRRT: Bodei and colleagues look at 2 predictive markers for response to and monitoring of peptide-receptor radionuclide therapy in neuroendocrine tumors and evaluate the predictive contributions of tissue-based genetic alterations. . . . . ***Page 567***

Sequencing ^{223}Ra and ^{177}Lu-PSMA: Rahbar and colleagues document safety and survival outcomes in patients with bone-predominant metastatic castration-resistant prostate cancer treated with ^{177}Lu-PSMA after ^{223}Ra therapy. . . ***Page 574***

^{18}F-PSMA versus ^{18}F-fluorocholine PET/CT: Olivier and colleagues compare ^{18}F-PSMA-1007 PET/CT and ^{18}F-fluorocholine PET/CT for localization of suspected biochemical recurrence of prostate cancer and for associated clinical management. . . . . ***Page 579***

^{18}F-Fluciclovine PET-guided radiotherapy: Lawal and colleagues analyze data from the EMPIRE-1 study, which compared fluciclovine PET/CT and conventional imaging in guiding prostate cancer salvage radiotherapy, here stratifying by protocol-specified criteria and comparing failure-free rates. . . . . ***Page 586***

^{68}Ga-PSMA11 and ^{68}Ga-RM2 PET for HIFU: Duan and colleagues evaluate a novel approach using both ^{68}Ga-RM2 and ^{68}Ga-PSMA11 PET/MRI in patients with localized prostate cancer before and after high-intensity focused ultrasound therapy to assess target tumor localization and response to treatment. . . . . ***Page 592***

Translation of ^{18}F-PSMA CLI and FAR CLI: Fragoso Costa and colleagues assess the value of Cerenkov luminescence imaging with flexible autoradiography and with ^{18}F-PSMA-1007 in preclinical studies and in patients with high-risk prostate cancer. . . . . ***Page 598***

Systematic PSMA PET response assessment: Kind and colleagues analyze the suitability of a semiautomatic prognostic approach by comparing ^{18}F-PSMA-1007 with ^{68}Ga-PSMA-11 PET/CT data for prediction of overall survival in patients with prostate cancer before ^{177}Lu-PSMA radioligand therapy. . . . . ***Page 605***

^{177}Lu-EB-PSMA RLT in mCRPC: Wang and colleagues investigate the safety and therapeutic efficacy of radioligand therapy with ^{177}Lu-EB-PSMA in patients with previously treated metastatic castration-resistant prostate cancer. . . . . ***Page 611***

^{68}Ga-FAPI-46 at 3 time points: Naeimi and colleagues monitor uptake on PET at 10 min, 1 h, and 3 h after ^{68}Ga-FAPI-46 administration in a spectrum of tumor types, with resulting implications for improving workflow and patient wait times. . . . . ***Page 618***

FAP-based PET imaging: Kashyap and Ravi Kumar review the current status and future promise of fibroblast-activation protein inhibitor–based imaging, including the ability to address specific limitations of ^{18}F-FDG PET and to provide both new and complementary biologic insights. . . . ***Page 623***

^{18}F-FAPI-04 PET/CT response prediction in LA-ESCC: Hu and colleagues examine whether ^{18}F-AlF-NOTA-fibroblast-activation protein inhibitor-04 PET/CT can predict short-term outcomes in patients with locally advanced esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. . . . . ***Page 625***

^{18}F-AlF-OC versus ^{68}Ga-DOTA-SSA PET: Pauwels and colleagues detail the results of a multicenter trial comparing the diagnostic performances of ^{18}F- and ^{68}Ga-labeled somatostatin analog PET tracers in patients with neuroendocrine tumors. . . . . ***Page 632***

Theranostic peptides targeting integrin $\alpha_v\beta_6$: Ganguly and colleagues describe development and testing of a novel $\alpha_v\beta_6$-targeting peptide, ^{68}Ga-DOTA-5G, and its DOTA-albumin-binding moiety for PET/CT imaging and with ^{177}Lu labeling for treatment. . . . . ***Page 639***

Myocardial efficiency in mitral regurgitation: Sorensen and colleagues use ^{11}C-acetate PET to noninvasively measure myocardial mechanical external efficiency, the energetic ratio of external cardiac work and left ventricular oxygen consumption. . . . . ***Page 645***

Deep learning for CAC on SPECT/CT: Miller and colleagues evaluate CT attenuation correction quantification derived from SPECT/CT myocardial perfusion maps using a deep learning model, including correlation with expert annotations and associations with major adverse cardiovascular events. . . . . ***Page 652***

Spatial normalization with deep learning: Kang and colleagues present a novel method for automatic quantification of amyloid PET using deep learning–based spatial normalization of PET images, which does not require MR or CT images of the same patient. . . . . ***Page 659***

CXCR4 expression in meningioma: Krebs and colleagues report on a clinical experience detecting C-X-C chemokine receptor 4 expression in meningioma with ^{68}Ga-pentixafor PET. . . . . ***Page 667***